Yoga During Anthracycline Chemo: A Promising HRV Trial

Anthracycline chemotherapy can affect more than the heart's pumping strength. It can also impair the autonomic nervous system that regulates heartbeat-to-heartbeat control. Yoga may help preserve that function, but the direct evidence comes from one small randomized trial whose key outcome numbers are not available in the published information reviewed here.

That distinction matters. Heart-rate variability (HRV) is a useful physiological marker, not proof that an intervention prevents heart failure, arrhythmias, or a decline in ejection fraction. For people receiving anthracyclines, yoga can be a reasonable supportive practice when their oncology team approves it. It is not a replacement for symptom reporting, echocardiography, or cardio-oncology care.

Chemo can affect the heart's nervous-system control

Anthracyclines such as epirubicin are well known for potential cardiac toxicity. The concern usually centers on myocardial contractility: whether the heart muscle can still pump effectively. But cardiac autonomic dysfunction appears to be a separate pathway. Reduced parasympathetic, or vagal, activity can show up as lower HRV, including lower high-frequency (HF) power.

A 2023 randomized trial by Inbaraj et al. framed autonomic impairment during anthracycline treatment as independent of contractility decline. That makes HRV a sensible target for research, although it remains a surrogate endpoint rather than a patient-centered cardiac outcome.

There is also emerging clinical reason to pay attention to HRV during treatment. In a prospective study of breast-cancer patients receiving anthracyclines and/or trastuzumab, Luna-Alcalá et al. in 2024 found that HRV-based indices predicted early cardiotoxicity. This is an association, not evidence that changing HRV changes cardiotoxicity risk. Trastuzumab co-treatment also makes it impossible to isolate an anthracycline-specific signal in that cohort.

The yoga trial tested a practical but demanding program

Inbaraj and colleagues randomly assigned 68 patients with stage I–III breast cancer to yoga plus treatment as usual or treatment as usual alone, with 34 participants in each group. All received six cycles of epirubicin 80 mg/m² plus cyclophosphamide 500 mg/m² every 21 days. The study used a single-blind, parallel-arm design and followed participants through an 18-week intervention.

The yoga group was prescribed 40-minute sessions five days per week. The program combined loosening exercises, postures, pranayama, meditation, and imagery-based relaxation. Its breathing component used a 1:2 inhale-to-exhale ratio, intended to increase parasympathetic modulation.

This was not a token "wellness" add-on. It was a structured intervention delivered alongside active chemotherapy. All participants attended the in-person sessions, while more than 80% completed at least three home sessions per week. That adherence figure is encouraging, but it also means the delivered home dose often fell below the five-session weekly prescription. A study cannot cleanly establish the benefit of a dose that many participants did not receive.

The missing result prevents an efficacy claim

The trial assessed HRV measures that included RMSSD, pNN50, HF power, and the LF/HF ratio after six chemotherapy cycles. Those are the measures needed to answer the central question: did yoga preserve autonomic function better than usual care?

The available report information does not provide the between-group HRV effect estimates, confidence intervals, or statistical results for those outcomes. Without them, readers cannot judge the size of any difference, whether chance could explain it, or whether a biomarker change would be clinically meaningful. The study supports a credible hypothesis and documents a feasible protocol. It does not, on the evidence available here, establish that yoga protected cardiac autonomic function during chemotherapy.

Yoga during chemotherapy is plausible as supportive care. It remains unproven as a strategy to prevent anthracycline-related cardiac injury.

Why the biological idea is still plausible

Yoga and breath-focused practices can influence autonomic measures in other populations. A 2025 randomized trial in women with hypothyroidism found that 12 weeks of yoga therapy improved HRV and baroreflex sensitivity. A separate 2025 randomized trial found that 12 weeks of Anulom Vilom pranayama, added to usual care, improved cardiac autonomic balance in people with mild-to-moderate Parkinson's disease.

These trials show that sustained yoga-based practice can shift autonomic measures over weeks. They do not tell us how much benefit to expect during epirubicin-cyclophosphamide treatment. Hypothyroidism, Parkinson's disease, and chemotherapy exposure affect autonomic function through different biology. A favorable HRV result in one condition does not travel intact to another like a carry-on bag.

The broader cancer literature points in the same direction without closing the gap. A 2021 systematic review and meta-analysis concluded that exercise interventions can reduce autonomic dysfunction in cancer patients and survivors. However, the available evidence did not separate active-treatment participants from survivors, so its relevance to active anthracycline therapy remains uncertain. A 2024 Tai Chi meta-analysis also found measurable HRV effects across clinical populations, offering a related mind-body benchmark rather than direct evidence for yoga during chemotherapy.

Why comparisons can mislead

HRV is sensitive to disease context, medication exposure, measurement conditions, and the exact intervention. Yoga studies differ in postures, breathing technique, session length, frequency, and duration. The 1:2 breathing pattern in the breast-cancer trial is not interchangeable with Anulom Vilom or Uddiyana Bandha.

Acute and chronic findings also answer different questions. A 2025 randomized study of Uddiyana Bandha in people with hypertension measured the immediate HRV response to a single session. It supports the idea that breathing practices can acutely engage autonomic regulation. It does not demonstrate training-induced adaptation over 12 or 18 weeks.

Even exercise-HRV findings from other chronic diseases require restraint. A 2021 meta-analysis in type 2 diabetes found that exercise training improved HRV, but diabetic cardiac autonomic neuropathy reflects metabolic and microvascular injury. That differs materially from chemotherapy-associated autonomic impairment, so its effect sizes should not become informal targets for cancer care.

What patients can reasonably do now

For a patient receiving anthracycline chemotherapy, supervised or oncology-approved yoga may be a practical way to support movement, breathing practice, and stress management. The tested protocol used 40 minutes per session, five days per week, for 18 weeks, but most participants met a lower home-practice threshold of at least three sessions weekly. Physical limitations, infection risk, ports, neuropathy, bone health, dizziness, and treatment-day fatigue all deserve individual adjustment.

Consumer HRV tracking can be interesting, but it should not become self-directed cardiac surveillance. Day-to-day values vary with sleep, illness, hydration, alcohol, training load, and device methods. A falling trend does not diagnose cardiotoxicity; a reassuring reading does not clear someone to ignore symptoms. New breathlessness, chest discomfort, palpitations, fainting, swelling, or a sharp fall in exercise tolerance warrant clinical attention.

The fair conclusion is narrow: yoga is biologically plausible and feasible during epirubicin-cyclophosphamide chemotherapy, and HRV is a relevant research target. A larger multicenter trial with complete HRV reporting and clinical cardiac outcomes is needed before yoga can be presented as cardioprotection.